v3.25.3
Segment Information (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
segment
Sep. 30, 2024
USD ($)
Segment Reporting [Abstract]        
Number of operating segments | segment     1  
Number of reportable segments | segment     1  
Segment Reporting Information [Line Items]        
Total research and development expenses $ 47,928 $ 65,982 $ 159,271 $ 182,252
Total selling, general, and administrative expenses 70,106 67,219 204,566 216,123
Reportable Segment        
Segment Reporting Information [Line Items]        
Personnel compensation and related costs 21,539 23,405 68,067 82,622
Licensing fees 0 22,634 19,997 22,634
CROs/CMOs/Investigators expenses 18,707 13,004 48,472 57,213
Other costs 7,682 6,939 22,735 19,783
Total research and development expenses 47,928 65,982 159,271 182,252
Clinical programs 18,179 23,060 63,236 63,196
Pre-Clinical programs 1,982 14,461 10,365 19,649
Unallocated research and development expenses 27,767 28,461 85,670 99,407
Total selling, general, and administrative expenses 70,106 67,219 204,566 216,123
Selling and marketing expenses 47,179 43,473 135,882 140,342
General and administrative expenses 22,927 23,746 68,684 75,781
Reportable Segment | Selling, general and administrative        
Segment Reporting Information [Line Items]        
Personnel compensation and related costs 41,320 39,984 124,642 134,157
Other costs $ 28,786 $ 27,235 $ 79,924 $ 81,966